IGMS News and Press, IGM Biosciences Inc.

2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 33.8% to $0.0788 on volume of 1,221,538,672 shares Akoustis Technologies Inc. (AKTS) rose 128.8% to $0.3151 on volume of 536,119,838 shares Crown Electrokinetics Corp. (CRKN) rose 3.1% t...

2024-05-22 11:44:10 ET More on IGM Biosciences IGM Biosciences: Unlikely To Move The Needle Again In 2024 IGM Biosciences GAAP EPS of -$0.83 misses by $0.01, revenue of $0.5M misses by $0.28M IGM Biosciences announces refocusing of Sanofi collaboration Seekin...

IGM Biosciences, Inc. (NASDAQ: IGMS) is one of today's top gainers. The company's shares have moved 38.57% on the day to $11.65. IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and infla...

2024-05-22 10:00:31 ET More on etc. Replimune: Continuing To Justify The Bear Thesis (For Now) Gold At $3,000 Is The Wrong Way To Think About The Precious Metal Best Buy: Poised For Growth Amid E-Commerce Threat Nvidia’s upcoming earnings has investors...

2024-05-11 23:18:05 ET Summary IGM Biosciences is developing a different class of antibodies to improve on the classic IgG antibodies. Their most advanced project, aplitabart, is being tested in a clinical trial for metastatic colorectal cancer. The company has a decent cash p...

2024-05-09 12:44:06 ET More on IGM Biosciences IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points IGM Biosciences announces refocusing of Sanofi collaboration IGM Biosciences GAAP EPS of -$1.01 beats by $0.08, revenue of $0.7M misses by $0....

- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a c...

MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conferenc...